Polycystic ovary syndrome

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 123-147

  Nandi, Anindita ^a   Chen, Zijian ^a   Patel, Ronak ^a   Poretsky, Leonid ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Insulin resistance; Long term effects; Polycystic ovary syndrome; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; ENDOMETRIUM CANCER; FEMALE INFERTILITY; GENETIC PREDISPOSITION; HEREDITY; HIRSUTISM; HORMONE ACTION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; MENTAL DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; COMPLICATION; FEMALE; METABOLISM; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME;

FEMALE; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 84896859678     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.10.003     Document Type: Review

References (153)

1. Hanson A.E. Hippocrates: diseases of women 1. Signs (Chic) 1975, 1:567-584.
2. Temkin O. Soranus' gynecology 1991, The Johns Hopkins University Press, Baltimore (MD).
3. Rosner F., Munter S. The medical aphorism of Moses Maimonides 1971, vol. 2. Yeshiva University Press, New York.
4. Achard E.C., Thiers J. Le virilisme et son association a l'insuffisnace glycolytique (diabete des femme a barbe). Bull Acad Natl Med 1921, 86:51.
5. Kovacs C., Smith J. Aguide to the polycystic ovary: its effects on health and fertility 2002, TFM Publishing, Castle Hill Barns (United Kingdom).
6. Stein I.F., Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29:181-191.
7. Carmina E., Lobo R. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. JClin Endocrinol Metab 1999, 84:1897-1899.
8. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005, 83(5):1343-1346.
9. Michelmore K., Ong K., Mason S., et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001, 55(4):439-446.
10. Norman R.J., Hague W.M., Masters S.C., et al. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod 1995, 10(9):2258-2261. [PubMed: 8530647].
11. Brassard M., AinMelk Y., Baillargeon J.P., et al. Basic infertility including polycystic ovary syndrome. Med Clin North Am 2008, 92:1163-1192. Xi.
12. Azziz R., Carmina E., Dewailly D., et al. Task force on the phenotype of the polycystic ovary syndrome of the Androgen Excess and PCOS Society: the Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 91:456-488.
13. Azziz R., Carmina E., Dewailly D., et al. Androgen Excess Society: position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. JClin Endocrinol Metab 2006, 91:4237-4245.
14. Norman R.J., Dewailly D., Legro R.S., et al. Polycystic ovary syndrome. Lancet 2007, 370:685-697.
15. Wild R.A., Painter P.C., Coulson P.B., et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. JClin Endocrinol Metab 1985, 61:946-951.
16. Wild R.A., Bartholomew M.J. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome. Am J Obstet Gynecol 1988, 159:423-427.
17. Dunaif A., Finegood D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. JClin Endocrinol Metab 1996, 81:942-947.
18. O'Meara N., Blackman J.D., Ehrmann D.A. Defects in beta-cell function in functional ovarian hyperandrogenism. JClin Endocrinol Metab 1993, 76:1241-1247.
19. Dunaif A., Segal K.R., Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
20. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
21. Diamanti-Kandarakis E., Papavassiliou A.G. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006, 12:324-332.
22. Legro R.S., Castracane V.D., Kauffman R.P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004, 59:141-154.
23. Vrbikova J., Cibula D., Dvorakova K., et al. Insulin sensitivity in women with polycystic ovary syndrome. JClin Endocrinol Metab 2004, 89:2942-2945.
24. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. JClin Endocrinol Metab 1999, 84:165-169.
25. Barr E.L., Magliano D.J., Zimmet P.Z., et al. AusDiab 2005: the Australian diabetes, obesity and lifestyle study 2006, International Diabetes Institute, Melbourne (Australia).
26. Legro R.S., Gnatuk C.L., Kunselman A.R., et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. JClin Endocrinol Metab 2005, 90:3236-3242.
27. Boudreaux M.Y., Talbott E.O., Kip K.E., et al. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 2006, 6:77-83.
28. Alberti K.G., Zimmet P., Shaw J. International Diabetes Federation: a consensus on Type 2 Diabetes prevention. Diabet Med 2007, 24:451-463.
29. Coffey S., Mason H. The effect of polycystic ovary syndrome on health-related quality of life. Gynecol Endocrinol 2003, 17:379-386.
30. Deeks A., Gibson-Helm M., Teede H. Anxiety and depression in polycystic ovary syndrome (PCOS): a comprehensive investigation. Fertil Steril 2010, 93:2421-2423.
31. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. JClin Endocrinol Metab 2004, 89(6):2745-2749.
32. Carmina E., Koyama T., Chang L., et al. Does ethnicity influence prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1992, 167(6):1807-1812.
33. Legro R.S. Phenotype and genotype in polycystic ovary syndrome. Polycystic ovary syndrome 2007, 25-41. Cambridge University Press, Cambridge (United Kingdom). G. Kovacs, R. Norman (Eds.).
34. Legro R.S., Driscoll D., Strauss J.F., et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998, 95:14956-14960.
35. Jahantar S., Eden J.A., Warren P., et al. Atwin study of polycystic ovary syndrome. Fertil Steril 1995, 63:478-486.
36. Ibanez L., DiMartino-Nardi J., Potau N., et al. Premature adrenarche: normal variant or forerunner of adult disease?. Endocr Rev 2000, 21:671-696.
37. Ibanez L., Potau N., Chacon P., et al. Hyperinsulinemia, dyslipidemia, and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998, 41:1057-1063.
38. Ibanez L., Potau N., Zampolli M., et al. Hyperinsulinemia and decreased insulin-like growth factor binding protein-I are common features in prepubertal and pubertal girls with a history of premature pubarche. JClin Endocrinol Metab 1999, 82:2283-2288.
39. Ibanez L., Potau N., Zampolli M., et al. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. Fertil Steril 1997, 67:849-855.
40. Ibanez L., Potau N., Zampolli M., et al. Source localization of androgen excess in adolescent girls. JClin Endocrinol Metab 1994, 79:1778-1784.
41. Zweig S.B., Tolentino M.C., Strizhevsky M., et al. Polycystic ovary syndrome. Principles of diabetes mellitus 2010, 515-530. Springer, New York. L. Poretsky (Ed.).
42. Barker D.J. The developmental origins of chronic adult disease. Acta Paediatr Suppl 2004, 93:26-33.
43. Ibanez L., Potau N., Francois J., et al. Pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. JClin Endocrinol Metab 1998, 83:3558-3562.
44. Ibanez L., Potau N., Zampolli M., et al. Hyperinsulinemia in post pubertal girls with a history of premature pubarche and functional ovarian hyperandrogenism. JClin Endocrinol Metab 1996, 81:1237-1243.
45. Manikkam M., Crespi E.J., Doop D.D., et al. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch up growth in sheep. Endocrinology 2004, 145:790-798.
46. Slob A.K., denHamer R., Woutersen P.J., et al. Prenatal testosterone propionate and postnatal ovarian activity in the rat. Acta Endocrinol 1983, 103:420-427.
47. Laitinen J., Taponen S., Martikainen H., et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003, 27:710-715.
48. Sadrzadeh S., Klip W.A., Broekmans F.J., et al. Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort. Hum Reprod 2003, 18:2225-2230.
49. Prentice A.M. Early influences on human energy regulation(CHECK):thrifty genotype and thrifty phenotypes. Physiol Behav 2005, 86:640-645.
50. Abbott D.H., Barnett D.K., Bruns C.M., et al. Androgen excess fetal programming of female reproduction: a developmental etiology for polycystic syndrome?. Hum Reprod Update 2005, 11:257-274.
51. Abbott DH, Eisner JR, Colman RJ, etal. Prenatal androgen excess programs for PCOS in female rhesus monkey. In: Chang RJ, Dunaif A, Hiendel J, editors. Polycystic ovary syndrome. New York: Marcel Dekker; 2002. p. 119-33.
52. Abbott G.H., Dumesic D.A., Eisner J.R., et al. Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkey. Trends Endocrinol Metab 1998, 9:62-64.
53. Dumesic D.A., Abbott D.H., Eisner J.R., et al. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril 1997, 67:155-163.
54. Eisner J.R., Barnett M.A., Dumesic D.A., et al. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril 2002, 77:167-172.
55. Abbott D.H., Foong S.C., Barnett D.K., et al. Nonhuman primates contribute unique understanding to anovulatory infertility in women. ILAR J 2004, 45:116-131.
56. Dumesic D.A., Schramm R.D., Peterson E., et al. Impaired developmental competence of oocytes in adult prenatally androgenized female rhesus monkeys undergoing gonadotropin stimulation for invitro fertilization. JClin Endocrinol Metab 2002, 87:1111-1119.
57. Dumesic D.A., Schramm R.D., Peterson E., et al. Reduced intrafollicular androstenedione and estradiol levels in early treated prenatally androgenized female rhesus monkeys receiving FSH therapy for invitro fertilization. Biol Reprod 2003, 69:1213-1219.
58. Eisner J.R., Dumesic D.A., Kemnitz J.W., et al. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. JClin Endocrinol Metab 2000, 85:1206-1210.
59. Eisner J.R., Dumesic D.A., Kemnitz J.W., et al. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes Res 2003, 11:279-286.
60. Yildiz B.O., Yarali H., Oguz H., et al. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. JClin Endocrinol Metab 2003, 88:2031-2036.
61. Kaushal R., Parchure N., Bano G., et al. Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries. Clin Endocrinol 2004, 60:322-328.
62. Bruns C.M., Baum S.T., Colman R.J., et al. Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. JClin Endocrinol Metab 2004, 89:6218-6223.
63. Dunaif A., Graf M., Mandeli J., et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. JClin Endocrinol Metab 1987, 65:499-507.
64. Liao E., Poretsky L. Polycystic ovary syndrome and its complications. Contemporary diabetes: obesity and diabetes 2006, 255-276. Humana Press Inc, New Jersey. C.S. Mantzoros (Ed.).
65. Robinson S., Kiddy D., Gelding S.V., et al. The relationship of insulin sensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol 1993, 39:351-355.
66. Ehmann D.A., Barnes R.B., Rosenfield R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141-146.
67. Pierpoint T., McKeigue D.M., Isaacs A.J., et al. Mortality of women with polycystic ovary syndrome at long-term follow up. JClin Epidemiol 1998, 51:581-586.
68. Kousta E., Franks S. Long term health consequences of polycystic ovary syndrome. Polycystic ovary syndrome 2007, 81-101. Cambridge University Press, Cambridge (United Kingdom). G. Kovacs, R. Norman (Eds.).
69. Salehi M., Bravo-Vera A., Sheikh A., et al. Pathogenesis of polycystic ovary syndrome: what is the role of obesity?. Metabolism 2004, 53:358-376.
70. Vrbikova J., Cifkova R., Jirkovska A., et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod 2003, 18:980-984.
71. Mather K.J., Kwan F., Corenblum B., et al. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000, 73:150-156.
72. Pirwany I.R., Fleming R., Greer I.A., et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 2001, 54:447-453.
73. Legro R.S., Kunselman A.R., Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001, 111:607-613.
74. Taponen S., Martikainen H., Jarvelin M.R., et al. Metabolic cardiovascular disease risk factors in women with self reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1996 Study. JClin Endocrinol Metab 2004, 89:2114-2118.
75. Diamanti-Kandarakis E., Spina G., Kouli C., et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. JClin Endocrinol Metab 2001, 86:4666-4673.
76. Orio F., Palomba S., Cascella T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. JClin Endocrinol Metab 2004, 89:4588-4593.
77. Kelly C., Lyall H., Petrie J.R., et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. JClin Endocrinol Metab 2001, 86:2453-2455.
78. Tarkun I., Arslan B.C., Canturk Z., et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. JClin Endocrinol Metab 2004, 89:5592-5596.
79. Talbott E.O., Guzick D.S., Sutton-Tyrell K., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20:2414-2421.
80. Christian R.C., Dumesic D.A., Behrenbeck T., et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. JClin Endocrinol Metab 2003, 88:2562-2568.
81. Dahlgren E., Janson P.O., Johansson S., et al. Polycystic ovary syndrome and risk for myocardial infarction, evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992, 71:599-604.
82. Wild S., Pierpont T., McKeigue P., et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 52:595-600.
83. Coulam C.B., Annegers J.F., Kranz J.S. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983, 61:403-447.
84. Hardiman P., Pillay O.C., Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003, 361:1810-1812.
85. Jun Z.Q., Pang L.H., Li M.J., et al. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013, 11:56.
86. Hsin H., Kenyon C. Signals from the reproductive system regulate the lifespan of C. elegans. Nature 1999, 399:362.
87. Bohni R., Riesgo-Escovar J., Oldham S., et al. Autonomous control of cell and organ size by CHICO, a Drosophila homologue of vertebrate IRS1-4. Cell 1999, 97(7):865.
88. Withers D.J. Insulin receptor substrate proteins and neuroendocrine function. Biochem Soc Trans 2001, 29:525.
89. Nandi A., Wang X., Accili D., et al. The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. Endocrinology 2010, 151(4):1863-1871.
90. Lautatzis M.E., Goulis D.G., Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism 2013, 62(11):1522-1534.
91. Zheng J., Shan P.F., Gu W. The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. JEndocrinol Invest 2013, [Epub ahead of print].
92. Glueck C.J., Goldenberg N., Pranikoff J., et al. Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. Curr Med Res Opin 2013, 29(1):55-62.
93. Roldan B., Escobar-Morreale H.F. The pediatric origins of polycystic ovary syndrome. Polycystic ovary syndrome 2007, 233-261. Cambridge University Press, Cambridge (United Kingdom). G. Kovacs, R. Norman (Eds.).
94. Rackow B.W. Polycystic ovary syndrome in adolescents. Curr Opin Obstet Gynecol 2012, 24:281-287.
95. Nicandri K.F., Hoeger K. Treatment and diagnosis of PCOS in adolescents. Curr Opin Endocrinol Diabetes Obes 2012, 19:497-504.
96. Apter D., Butzon T., Laughlin G.A., et al. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. JClin Endocrinol Metab 1995, 80:2966-2973.
97. Mauras N., Welch S., Rini A., et al. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole body protein metabolism in post pubertal young females: a metabolic study. JClin Endocrinol Metab 1998, 83:1900-1905.
98. Arsalanian S.A., Lewy V.D., Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and B cell dysfunction and risk of cardiovascular disease. JClin Endocrinol Metab 2001, 86:66-71.
99. Frank S. Polycystic ovary syndrome. NEngl J Med 1995, 333:853-861.
100. Kahn C.R., Flier J.S., Bar R.S., et al. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 1975, 190:63-65.
101. Kahn C.R., Flier J.S., Bar R.S., et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. NEngl J Med 1976, 294:739-745.
102. Poretsky L., Bhargava G., Kalin M.F., et al. Regulation of insulin receptors in the human ovary: invitro studies. JClin Endocrinol Metab 1988, 67:774-778.
103. Poretsky L., Bhargava G., Saketos M., et al. Regulation of human ovarian insulin receptors invivo. Metabolism 1990, 39:161-166.
104. Nandi A, Poretsky L. Diabetes and the female reproductive system. Endocrinol Metab Clin North Am, in press.
105. Poretsky L., Smith D., Seibel M., et al. Specific insulin binding sites in human ovary. JClin Endocrinol Metab 1984, 59:809-811.
106. Poretsky L., Grigorescu F., Seibel M., et al. Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. JClin Endocrinol Metab 1985, 61:728-734.
107. Barbieri R.L., Makris A., Ryan K.J. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril 1983, 40:237-241.
108. Willis D., Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. JClin Endocrinol Metab 1995, 80:3788-3790.
109. Poretsky L., Cataldo N.A., Rosenwaks Z., et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999, 20(4):535.
110. Voutilainen R., Franks S., Mason H.D., et al. Expression of insulin-like growth factor (IGF), IGF binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. JClin Endocrinol Metab 1996, 81(3):1003.
111. Rosenfeld R.G., Rosenbloom A.L., Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994, 15(3):369.
112. Poretsky L., Chun B., Liu H.C., et al. Insulin-like growth factor II (IGF-II) inhibits insulin-like growth factor binding protein I (IGFBP-1) production in luteinized human granulosa cells with a potency similar to insulin-like growth factor I (IGF-I). JClin Endocrinol Metab 1996, 81(9):3412.
113. Damario M.A., Bogovixh K., Hung-Ching L., et al. Synergistic effects of insulin-like growth factor-I and human chorionic gonadotropin in the rat ovary. Metabolism 2000, 49:314-320.
114. Poretsky L. Commentary: polycystic ovary syndrome-increased or preserved ovarian sensitivity to insulin?. JClin Endocrinol Metab 2006, 91:2859-2860.
115. Dunaif A., Xia J., Book C.B., et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. JClin Invest 1995, 96:801-810.
116. Cheatham B., Kahn C.R. Insulin action and the insulin signaling network. Endocr Rev 1995, 16:117-142.
117. Nestler J.E., Jakubowicz D.J., de Vargas A.F., et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. JClin Endocrinol Metab 1998, 83(6):2001.
118. Shoupe D., Lobo R.A. The influence of androgens on insulin resistance. Fertil Steril 1984, 41(3):385.
119. Yan X., Dai X., Wang J., et al. Prenatal androgen excess programs metabolic derangements in pubertal female rats. JEndocrinol 2013, 217:119-129.
120. Lewy V.D., Danadian K., Witchel S.F., et al. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. JPediatr 2001, 138:38-44.
121. Sir-Petermann T., Codner E., Perez V., et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. JClin Endocrinol Metab 2009, 94:1923-1930.
122. Hojlund K., Glintborg D., Andersen N.R., et al. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 2008, 57:357-366.
123. Semple R., Savage D., Cochran E., et al. Genetic syndromes of severe insulin resistance. Endocr Rev 2011, 32:498-514.
124. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33:981-1030.
125. Shi Y., Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
126. Chang H., Brown C.W., Matzuk M.M. Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr Rev 2002, 23:787-823.
127. Miralles F., Czernichow P., Scharfmann R. Follistatin regulates the relative proportions of endocrine versus exocrine tissue during pancreatic development. Development 1998, 125:1017-1024.
128. Gonzalez-Cadavid N.F., Bhasin S. Role of myostatin in metabolism. Curr Opin Clin Nutr Metab Care 2004, 7:451-457.
129. Chen Z.J., Zhao H., He L., et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011, 43:55-59.
130. Goodarzi M.O., Jones M.R., Li X., et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. JMed Genet 2012, 49:90-95.
131. Jones M.R., Chua A.K., Mengesha E.A., et al. Metabolic and cardiovascular genes in polycystic ovary syndrome: a candidate-wide association study (CWAS). Steroids 2012, 77:317-322.
132. Kadowaki T., Bevins C.L., Cama A., et al. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 1988, 240:787-790.
133. Yoshimasa Y., Seino S., Whittaker J., et al. Insulin resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 1988, 240:784-787.
134. Magsino C., Spencer J. Insulin receptor antibodies and insulin resistance. South Med J 1999, 92:717-719.
135. George S., Rochford J.J., Wolfrum C., et al. Afamily with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004, 304:1325-1328.
136. Dash S., Sano H., Rochford J.J., et al. Atruncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc Natl Acad Sci USA 2009, 106:9350-9355.
137. Garg A. Lipodystrophies: genetic and acquired body fat disorders. JClin Endocrinol Metab 2011, 96:3313-3325.
138. Caballero E. Diabetes in culturally diverse populations: from biology to culture. Principles of diabetes mellitus 2010, 129-146. Springer, New York. L. Poretsky (Ed.).
139. Bates G.W., Whitworth N.S. Effect of body weight reduction on plasma androgens in obese fertile women. Fertil Steril 1982, 38:406-409.
140. Pasquali R., Antenucci D., Casimirri F., et al. Clinical and hormonal characteristics of obese and amenorrheic women before and after weight loss. JClin Endocrinol Metab 1989, 68:173-179.
141. Clark D.O. Physical activity efficacy and effectiveness among older adults and minorities. Diabetes Care 1997, 20:1176-1182.
142. Katsiki N., Hatzitolios A. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol 2010, 22:466.
143. Bloomgarden Z.T., Futterwiet W., Poretsky L. The use of insulin-sensitizing agents in patients with polycystic ovary syndrome. Endocr Pract 2001, 7:279-286.
144. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome p450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. NEngl J Med 1996, 335:617-623.
145. Moghetti P., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. JClin Endocrinol Metab 2000, 85(1):139-146.
146. Azziz R., Ehrmann D., Legro R.S., et al. Troglitazone improves ovulation and hirsutism in polycystic ovary syndrome: a multi-center, double blind placebo-controlled trial. JClin Endocrinol Metab 2001, 86:1626-1632.
147. Brettenthaler N., De Geyter C., Huber P., et al. Effect of insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. JClin Endocrinol Metab 2004, 89:3835-3840.
148. Garmes H., Tambascia M., Zantut-Wittmann P. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005, 21:317-323.
149. Seto-Young D., Paliou M., Schlosser J., et al. Thiazolidinedione action in the human ovary: insulin-independent and insulin sensitizing effects of steroidogenesis and insulin-like growth factor binding protein-1 production. JClin Endocrinol Metab 2005, 90:6099-6105.
150. Elter K., Imir G., Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized and control study. Hum Reprod 2002, 17(7):1729.
151. Lemay A., Dodin S., Turcot L., et al. Rosiglitazone and ethinyl-estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006, 21(1):121.
152. Ganie M.A., Khurana M.L., Nisar S., et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome: a six month, open-label randomized study. JClin Endocrinol Metab 2013, 98:3599-3607.
153. Araki T., Elias R., Rosenwaks Z., et al. Achieving a successful pregnancy in women with polycystic ovary syndrome. Endocrinol Metab Clin North Am 2011, 40:865-894.